MPM BioImpact, which manages over $3.5 billion and founded K2 in 2024, put up the full round. K2 runs eight programmes from pre-clinical to clinical, including antibody-drug conjugates and T-cell engagers.

Positive-sum angle: Singapore gains a drug-development bench that sources assets internationally and advances them locally — clinical operations talent that stays in the region between programmes.

Source — TNGlobal